• slider text 2

OUR PRODUCTS

Credo Diagnostics Biomedical develops point-of-care (POC) diagnostic technology.

Our nucleic acid diagnostic platform is designed to be used by any personnel with minimal training. Our solution covers sample preparation, amplification and detection through simple operating procedures with short turnaround time with no compromise on accuracy and sensitivity.

OUR VISION

We at Credo Diagnostics, the pioneers of accessible diagnostic platforms, want to improve the lives of those we love.

We believe providing the right information to the right people at the right time leads to better outcomes.

NEWS

2022
01-21
Credo Diagnostics will be present at Medical Japan Osaka in February 2022

Taiwan, January 21, 2022 –Credo Diagnostics will be present at Medical Japan Osaka in February 24-26, 2022. Please come and visit our booth!

 

Medical Japan is Japan’s leading trade show consisting of specialized shows for the Medical, Elderly Care and Pharmacy industries. The show will exhibit Medical IT, IT systems for hospitals, medical/hospital supplies, disposables, medical equipment, rehabilitation equipment, diagnostic equipment, clinical testing, advanced medical technologies, regenerative medicine, medical equipment development and manufacturing, pharmaceutical manufacturing, etc.

 

Credo Diagnostics will show a true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. Being conscious of the necessity to simplify processes and accelerate molecular testing at affordable costs, Credo Diagnostics has the leading position in providing effective rapid POC Molecular Diagnostics. At Medical Japan Osaka, a Japanese interpreter will also serve at our booth for further inquiries. We are pleased to invite you to visit our booth and get to know the most innovative POCT solution and rapid molecular diagnostic platform, VitaPCR™

 

【Medical Japan 2022 Osaka】

◾ Date: February 24 (Thu) - 26 (Sat), 2022

◾ Venue: INTEX Osaka, Japan(Virtual and Online)

◾ Booth No.: 9-21

◾ Exhibition Website: https://www.medical-jpn.jp/osaka/ja-jp.html

 

 

 


 

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

view more
2022
01-14
VitaPCR™Sample Collection Buffer Shows the Capability of Inactivating the SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV)

Taiwan, January 14, 2022--SARS-CoV-2, Influenza virus, and Respiratory syncytial virus (RSV) are the well-known pathogens responsible for several contagious respiratory diseases, which can cause mild to severe illness and even death. These pathogens can spread very quickly from person to person, simply by touching or breathing in virus-containing particles. A case in point is COVID-19, it has been the most prevailing contagion worldwide since late 2019. To identify the disease, billions of specimens have been collected by the frontline healthcare operators every day to perform the respective diagnostic tests. Therefore,  it is crucial to implement appropriate measures to reduce the risk of virus exposure and protect the healthcare operators carrying out the tests

 

In a study published in Nature Scientific Reports1, our VitaPCR™ Sample Collection Buffer was shown to effectively inactivate SARS-CoV-2 virus. In another inactivation study done by an external laboratory, treatment with the VitaPCR™ Sample Collection Buffer for 1 minute is capable of reducing Influenza A Virus, Influenza B Virus, and RSV titer by ≥ 4 log10 PFU/mL. Therefore, as the first step in our tests2 procedures, by mixing the patients’ swabs into our VitaPCR™ Sample Collection Buffer, the risk of virus exposure on testing operators is greatly reduced and therefore their safety is not compromised.  

 

As a leader in the development of advanced medtech diagnostics solutions, Credo Diagnostics is proud to announce that we have dedicated ourselves to not only providing excellent and accurate diagnostic solutions, what we have designed ensures that the operators in the front line are safe – truly in line with our mission of improving the lives of those we love. With the inactivation effectiveness on SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and RSV, there is no doubt our VitaPCR™ Sample Collection Buffer is one of the ideal tools in our VitaPCR™ solution.

 

For more information, please contact us at service@credodxbiomed.com

 

1.Davies, K., Arnold, U., Buczkowski, H. et al.Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Sci Rep11, 23379 (2021). https://doi.org/10.1038/s41598-021-02942-4

2. The VitaPCR™ Sample Collection Buffer is provided in VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Flu A&B Assay, VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay, and VitaPCR™ Flu/RSV Assay


 

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

view more
2022
01-12
Credo VitaPCR™ system is on board! To work with Explorer Dream to resume cruises in Taiwan.

Taiwan, January 12, 2022 – Credo Diagnostics, a leader in the development of advanced MedTech diagnostics solutions, is proud to announce that we have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號). By providing a true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology, cruise tours were able to resume.

 

In a close-contact environment like the cruise ship, the transmission risk of SARS-CoV-2 from person to a person significantly increases with the movement of large numbers of people in such a closed setting. Therefore, in addition to social distance and regular sanitization measures, testing for COVID-19 is also an important way to protect everyone regardless of vaccination status. The VitaPCR™ SARS-CoV-2 Assay, based on the proprietary RT-PCR technology, enables COVID-19 detection in 20 minutes to provide timely diagnosis, helping healthcare personnel make accurate and immediate healthcare management decisions on board.

 

Our VitaPCR™ SARS-CoV-2 Gen 2 Assay is able to detect COVID19 in 20 minutes with the all-important Ct value. By providing quick and accurate testing, the safety of the staff and crew members and passengers was not compromised. Importantly, Credo Diagnostics solution helps open up the resumption of the luxury cruise industry.

 

   

Credo Diagnostics have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號)

 

   

Credo Diagnostics solution helps open up the resumption of the luxury cruise industry.

 

 



About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

view more

CONTACT

We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.